Targets › TK2
3 programs from 3 companies in 4 trials: 2 Phase 2, 2 Phase 1; Neurology; next expected readout Dec 2026.
Phosphorylates thymidine, deoxycytidine, and deoxyuridine in the mitochondrial matrix. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on TK2 and DGUOK. Widely used as target of antiviral and chemotherapeutic agents. (UniProt, O00142)
Open in Phaseline: the race on TK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cristina Domínguez González | Doxecitine and Doxribtimine Nucleoside analogues for mitochondrial DNA synthesis in TK2 deficiency | TK2 | Phase 2 | Thymidine Kinase 2 (TK2 ) Deficiency | Jan 2027 |
| Kenneth Myers, MD | deoxycytidine and deoxythymidine (dC/dT) Nucleotide replacement therapy; supplies deoxycytidine and deoxythymidine to restore mitoc | TK2, DTYMK | Phase 2 | Mitochondrial Diseases | Jun 2029 |
| Columbia University | Thymidine Mitochondrial DNA nucleotide precursor; substrate for TK2-mediated conversion to deoxythym | TK2 | Phase 1 | Mitochondrial DNA Depletion Syndrome 2 Myopathic Type | Dec 2026 |
Mitochondrial DNA Depletion Syndrome 2 Myopathic Type (2) Mitochondrial Diseases (1) Thymidine Kinase 2 (TK2 ) Deficiency (1)
small molecule (3)
Kenneth Myers, MD (1) Columbia University (1) Cristina Domínguez González (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.